GHK-Cu vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticRecovery & RepairAnti-Aging & Longevity
GHK-CuGLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- GHK-Cu is a naturally occurring copper complex that declines with age. It is one of the most studied anti-aging peptides, known for powerful skin rejuvenation, wound healing, and tissue remodeling effects.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- 2–4 hours
- ~5 days
- Admin Route
- SubQ, Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 1–3 mg
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- 3–5 times per week
- Once weekly, subcutaneous
- Key Benefits
- Reduces wrinkles and fine lines
- Improves skin firmness and elasticity
- Accelerates wound healing
- Reduces inflammation and oxidative damage
- Promotes hair growth and thickness
- Supports collagen and elastin production
- May improve overall skin health and appearance
- Resets aged fibroblast behavior
- Anti-fibrotic — reduces scar tissue formation
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Temporary blue-green discoloration at injection site (from copper — harmless)
- Post-injection sting (brief)
- Skin irritation with topical use (rare)
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —